Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19

[1]  K. Anstrom,et al.  Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ) , 2023, International Journal of Infectious Diseases.

[2]  M. Hernán,et al.  Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers , 2022, Clinical Microbiology and Infection.

[3]  P. Pabla,et al.  Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study , 2021, International Journal of Infectious Diseases.

[4]  C. Guinovart,et al.  Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial , 2021, Trials.

[5]  M. Ezekowitz,et al.  Testing the feasibility of operationalizing a prospective, randomized trial with remote cardiac safety EKG monitoring during a pandemic , 2021, Journal of Interventional Cardiac Electrophysiology.

[6]  F. Syed,et al.  Pre-Exposure Prophylaxis with Various Doses of Hdroxychloroquine among high-risk COVID 19 Healthcare Personnel: CHEER randomized controlled trial , 2021, medRxiv.

[7]  R. Perez-Padilla,et al.  Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial , 2021, medRxiv.

[8]  G. Guyatt,et al.  Prophylaxis against covid-19: living systematic review and network meta-analysis , 2021, BMJ.

[9]  Sean M. O'Brien,et al.  Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials , 2021, Nature Communications.

[10]  A. Cook,et al.  Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial , 2021, International Journal of Infectious Diseases.

[11]  Anonymous.  Correction: Simultaneous COVID-19 in Monozygotic Twins , 2021, Annals of Internal Medicine.

[12]  M. T. Medina,et al.  Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results , 2020, The New England Journal of Medicine.

[13]  C. Tebé,et al.  A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 , 2020, The New England journal of medicine.

[14]  J. Goldman.  Hydroxychloroquine for Prevention of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: Challenges to Trial Conduct During the Global Pandemic , 2020, Clinical Infectious Diseases.

[15]  J. Goldman.  Hydroxychloroquine for Prevention of SARS-CoV-2 Infection: challenges to trial conduct during the global pandemic , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  R. Malekzadeh,et al.  Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results , 2020, medRxiv.

[17]  Jennifer L. Bell,et al.  Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19 , 2020, The New England Journal of Medicine.

[18]  J. Balko,et al.  Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial , 2020, medRxiv.

[19]  Emily G McDonald,et al.  A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 , 2020, The New England journal of medicine.

[20]  J. Baeten,et al.  Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial , 2020, Trials.

[21]  A. Bienvenu,et al.  Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020 , 2020, One Health.

[22]  K. Niburski,et al.  Impact of Trump's Promotion of Unproven COVID-19 Treatments and Subsequent Internet Trends: Observational Study , 2020, Journal of medical Internet research.

[23]  Xu Liu,et al.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  Issa J Dahabreh,et al.  Toward Causally Interpretable Meta-analysis: Transporting Inferences from Multiple Randomized Trials to a New Target Population. , 2020, Epidemiology.

[25]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[26]  Sander Greenland,et al.  Scientists rise up against statistical significance , 2019, Nature.

[27]  James M Robins,et al.  Per-Protocol Analyses of Pragmatic Trials. , 2017, The New England journal of medicine.

[28]  Gerta Rücker,et al.  The Hartung‐Knapp modification for random‐effects meta‐analysis: A useful refinement but are there any residual concerns? , 2017, Statistics in medicine.

[29]  Richard D. Riley,et al.  Random effects meta‐analysis: Coverage performance of 95% confidence and prediction intervals following REML estimation , 2016, Statistics in medicine.

[30]  Gerta Rücker,et al.  Hartung–Knapp method is not always conservative compared with fixed‐effect meta‐analysis , 2016, Statistics in medicine.

[31]  S. Goodman,et al.  Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations , 2016, European Journal of Epidemiology.

[32]  T. Friede,et al.  Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies , 2015, BMC Medical Research Methodology.

[33]  George F Borm,et al.  The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method , 2014, BMC Medical Research Methodology.

[34]  David J Spiegelhalter,et al.  A re-evaluation of random-effects meta-analysis , 2009, Journal of the Royal Statistical Society. Series A,.

[35]  A. Panlilio,et al.  Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. , 2005, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[36]  J. Hartung,et al.  A refined method for the meta‐analysis of controlled clinical trials with binary outcome , 2001, Statistics in medicine.

[37]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[38]  G. Sida,et al.  [Consensus Document on post-exposure prophylaxis against HIV, HBV and HCV in adults and children]. , 2016, Enfermedades infecciosas y microbiologia clinica.